{
    "id": 11164,
    "cites": 10,
    "cited_by": 1,
    "reference": [
        "Belth, J (2002). Viatical and Life Settlement Transactions. Contingencies.",
        "Centers for Disease Control and Prevention (2001). HIV/AIDS Surveillance Report 2001, Year-end edition. Volume 13, No. 2.",
        "Federal Trade Commission (2004). 1992 Horizontal Merger Guidelines - with April 8, 1997, revisions to section 4 on efficiencies. Online at http:// www.ftc.gov/bc/docs/horizmer.htm (as of Jan 18, 2004).",
        "Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998; 280:35-41.",
        "Gulick RM, Mellors JW, Havlir D, et al. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Annals of Internal Medicine 2000; 133:35-9.",
        "Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-33.",
        "Michigan Office of Financial and Insurance Services (OFIS), Press Release, Viatical Settlements Draw Warning From State Regulators, Congressional Scrutiny, February 27 2002.",
        "National Association of Insurance Commissioners (1999), Advisory Package on Viatical Settlements, Kansas City, Missouri.",
        "National Viatical Association (1999), NVA Information Booklet, Washington, DC.",
        "Sippel, E. and Buerger, A. (2002). A Free Market for Life Insurance, Contingencies. March/April."
    ]
}